This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| FOXO1 | |
|---|---|
| Name | FOXO1 |
| Other names | FKHR |
| Species | Human |
| Chromosome | Chromosome 13 |
| Location | 13q14.11 |
| Gene length | ≈27 kb |
| Protein length | 655 aa (human isoform) |
FOXO1 FOXO1 is a member of the forkhead box O family of transcription factors involved in cellular homeostasis, metabolism, proliferation, and stress responses. It integrates signals from kinases and signaling cascades to modulate transcriptional programs that influence development, tumor suppression, glucose metabolism, and apoptosis. Research on FOXO1 intersects with studies of signaling pathways, genetic disorders, cancer biology, and pharmacologic modulation.
FOXO1 functions as a transcriptional regulator with conserved forkhead DNA-binding motifs first characterized in studies of Drosophila melanogaster developmental regulators and later linked to mammalian regulators in investigations at institutions like Harvard Medical School, Yale University, and Stanford University. Early cloning efforts involved groups from National Institutes of Health and collaborations with Cold Spring Harbor Laboratory. FOXO1 research connects to landmark work on signaling from Insulin receptor, PI3K, AKT1, and stress kinase pathways examined in laboratories affiliated with Max Planck Society and European Molecular Biology Laboratory.
The FOXO1 locus on Chromosome 13 (human) encodes a protein with a conserved forkhead (winged-helix) DNA-binding domain identified by structural biologists at centers including Protein Data Bank contributors and crystallography groups at Scripps Research Institute. The protein contains nuclear localization signals and nuclear export sequences mapped using techniques developed at Cold Spring Harbor Laboratory and EMBL-EBI. Domain architecture studies referenced methods from NIH, Broad Institute, and Wellcome Trust Sanger Institute and are comparable to related family members studied in labs at University of Cambridge, University of Oxford, and Massachusetts Institute of Technology.
FOXO1 is regulated by phosphorylation by kinases such as AKT1, SGK1, and CDK2 and by dephosphorylation via phosphatases analyzed in research at Dana-Farber Cancer Institute and Mayo Clinic. Acetylation by acetyltransferases described by teams at Columbia University and deacetylation by SIRT1 were elucidated in studies affiliated with University of California, San Francisco and University of Texas Southwestern Medical Center. Ubiquitination pathways involving E3 ligases studied at Johns Hopkins University and SUMOylation work from University of Pennsylvania groups further modulate FOXO1 stability and activity. Cross-talk between signaling nodes including mTOR, AMPK, and MAPK1 has been reported by consortia such as Human Protein Atlas contributors and collaborative networks including Cancer Research UK.
FOXO1 controls transcriptional programs that affect gluconeogenesis via target genes characterized in studies linked to National Institute of Diabetes and Digestive and Kidney Diseases and interactions with PGC1α. It regulates cell cycle genes whose regulation was mapped in cancer centers like Memorial Sloan Kettering Cancer Center and influences apoptosis through targets investigated at Fred Hutchinson Cancer Research Center. FOXO1 participates in oxidative stress responses explored in laboratories at Imperial College London and modulates autophagy processes studied by teams at University of Cambridge and ETH Zurich. FOXO1 activity integrates inputs from pathways studied by researchers at European Molecular Biology Laboratory, Whitehead Institute, and Koch Institute.
FOXO1 is essential for vascular and cardiac development as shown in developmental biology research at University College London and Karolinska Institutet. It has roles in adipocyte differentiation investigated by groups at Roswell Park Comprehensive Cancer Center and in skeletal muscle remodeling studied at University of Michigan. FOXO1 influences pancreatic beta-cell function and differentiation described by teams at Joslin Diabetes Center and Baylor College of Medicine. Its roles in hematopoiesis and immune cell differentiation were characterized by immunology groups at National Jewish Health and Pasteur Institute.
Alterations affecting FOXO1 are implicated in cancers, notably chromosomal translocations and downstream pathway dysregulation explored at MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Royal Marsden Hospital. FOXO1-mediated dysregulation contributes to metabolic disorders studied at Imperial College London, Joslin Diabetes Center, and University of Cambridge Metabolic Research Laboratories. Links to cardiovascular disease and endothelial dysfunction were reported from studies at Cleveland Clinic and Stanford University School of Medicine. FOXO1 involvement in neurodegenerative processes has been examined by teams at National Institute on Aging and University College London Hospital. Clinical correlations and biomarker studies have been pursued in multicenter trials coordinated by networks including European Society for Medical Oncology and American Society of Clinical Oncology.
Therapeutic strategies targeting FOXO1 pathways include small molecules modulating upstream kinases developed by pharmaceutical groups at Pfizer, Novartis, Roche, and GlaxoSmithKline and investigational biologics evaluated in translational programs at Genentech and AstraZeneca. Gene editing and conditional knockout models implemented with CRISPR/Cas9 and Cre-lox systems were created in facilities associated with Jackson Laboratory and Broad Institute. High-throughput screening platforms and chemical probes used in FOXO1 studies derive from resources at NIH Chemical Genomics Center and compound libraries of European ScreeningPort collaborators. Analytical tools including ChIP-seq, RNA-seq, and proteomics were performed using infrastructure at EMBL-EBI, ProteomeXchange Consortium, and National Center for Biotechnology Information.
Category:Transcription factors